One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.

Hepatitis B vaccination of 113 hemophiliacs: lower antibody response in anti-LAV/HTLV-III-positive patients / A.R. ZANETTI, P.M. MANNUCCI, E. TANZI, G.A. MORONI, M. DE PASCHALE, M. MORFINI, V. CARNELLI, M.C. TIRINDELLI, R. DE BIASI, N. CIAVARELLA, V. DE ROSA, F. RODEGHIERO, M. COLOMBO. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 23:4(1986), pp. 339-345. [10.1002/ajh.2830230406]

Hepatitis B vaccination of 113 hemophiliacs: lower antibody response in anti-LAV/HTLV-III-positive patients

A.R. ZANETTI
Primo
;
P.M. MANNUCCI
Secondo
;
E. TANZI;V. CARNELLI;M. COLOMBO
Ultimo
1986

Abstract

One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.
Settore MED/42 - Igiene Generale e Applicata
1986
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/187790
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact